Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens

Detalhes bibliográficos
Autor(a) principal: Willadsen,P.
Data de Publicação: 1992
Outros Autores: Kemp,D. H., Cobon,G. S., Wright,I. G.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049
Resumo: Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials.
id FIOCRUZ-4_daf434a11792f6c4958c3afffd69adbc
oai_identifier_str oai:scielo:S0074-02761992000700049
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigensvaccinationBoophilus microplusBabesia bovisrecombinant antigensfield trialsCurrent methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials.Instituto Oswaldo Cruz, Ministério da Saúde1992-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049Memórias do Instituto Oswaldo Cruz v.87 suppl.3 1992reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02761992000700049info:eu-repo/semantics/openAccessWilladsen,P.Kemp,D. H.Cobon,G. S.Wright,I. G.eng2020-04-25T17:46:58Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:05:10.188Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
title Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
spellingShingle Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
Willadsen,P.
vaccination
Boophilus microplus
Babesia bovis
recombinant antigens
field trials
title_short Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
title_full Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
title_fullStr Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
title_full_unstemmed Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
title_sort Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
author Willadsen,P.
author_facet Willadsen,P.
Kemp,D. H.
Cobon,G. S.
Wright,I. G.
author_role author
author2 Kemp,D. H.
Cobon,G. S.
Wright,I. G.
author2_role author
author
author
dc.contributor.author.fl_str_mv Willadsen,P.
Kemp,D. H.
Cobon,G. S.
Wright,I. G.
dc.subject.por.fl_str_mv vaccination
Boophilus microplus
Babesia bovis
recombinant antigens
field trials
topic vaccination
Boophilus microplus
Babesia bovis
recombinant antigens
field trials
dc.description.none.fl_txt_mv Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials.
description Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials.
publishDate 1992
dc.date.none.fl_str_mv 1992-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0074-02761992000700049
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.87 suppl.3 1992
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937660509028352

Registros relacionados